Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moderate Dose Bolus IL-2 in Metastatic Melanoma
NCT01702896Phase 2Terminated
- Sponsor
- Western Regional Medical Center
- Start
- Sep 2012
- Primary completion
- Dec 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in melanoma, sponsored by Western Regional Medical Center. Started Sep 2012; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01702896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01702896.